Bluejay Diagnostics (BJDX) risk factors, FY2025 10-K

Bluejay Diagnostics's FY2025 10-K, filed Mar 06, 2026, lists 51 risk factors in 6 groups. Against the prior year's 56: 6 new, 11 dropped, 12 substantially reworded.

Open BJDX in Gloom →
Bluejay Diagnostics' chart, financials and news, free in your browser.Open BJDX in Gloom →
Risk factors listed
516 groups
New this year
6vs 56 last year
Dropped
11since the prior 10-K
Substantially reworded
12of those kept
Section length
18k wordsItem 1A

What the changes say

  • The company faces an acute cash shortage, requiring $20 million by 2027 to avoid bankruptcy while operating with only 6 employees.
  • Technical challenges with Symphony cartridges and specimen stability threaten the planned 2027 FDA 510(k) submission.

What changed since the prior 10-K

New

  • NewRisks Related to Our Financial Condition and Capital Requirements

    We expect to need to raise at least $20 million between the date of this filing and the end of the 2027 fiscal year, and failure to do so could require us to undertake a process of liquidation under U.S. bankruptcy laws, which could cause holders of our common stock to recoup little, if any, value for their shares

    The company needs at least $20 million by the end of 2027 and expects to run out of cash in the third quarter of 2026, risking liquidation.

  • NewRisks Related to Our Financial Condition and Capital Requirements

    Given the amount and terms of these warrants, we may find it more difficult to raise additional equity capital on favorable terms or at all while these warrants are outstanding

    Outstanding warrants and potential Nasdaq delisting if the stock price falls below $1.00 may make raising additional equity capital more difficult.

  • NewRisks Related to Our Business

    To preserve cash resources, we downsized our organization in 2025, which may reduce business continuity, affect our ability to apply for certain patents, and affect our product development and timelines

    Headcount was reduced to 6 full-time employees in 2025 to preserve cash, which may impair business continuity, patent filings, and product development timelines.

  • NewRisks Related to Our Business

    As an intermediate step to regulatory submission, we need to demonstrate that our collected clinical samples do not degrade over time

    Failure to demonstrate that IL-6 samples collected from the SYMON-II study remain stable over time could force a business plan redesign.

  • NewRisks Related to Our Business

    We might not be able to resolve certain causes of a Symphony performance reproducibility issue, and if the issues persist we might have to take a different approach

    Unresolved performance reproducibility issues with Symphony cartridges could delay the FDA clearance process.

  • NewRisks Related to Our Business

    Healthcare legislative reform measures could have a material adverse effect on our business, future revenue, if any, and results of operations

    Healthcare cost-containment initiatives and coverage limitations by Medicare, Medicaid, and private insurers could harm future commercial revenue.

Dropped

  • DroppedRisks Related to Our Financial Condition and Capital Requirements

    We will require additional funding to finance our operations to continue as a going concern, which may not be available to us on acceptable terms, or at all, and our lack of cash resources has slowed the timeline of our clinical trial work and could cause us to run out of cash resources in the near-term

  • DroppedRisks Related to Our Financial Condition and Capital Requirements

    The placement agent from our August 2023 Registered Direct Offering and January 2024 Public Offering could assert that they are entitled to a fee in connection with our June 2024 Public Offering

    Required additional funding and noted negative cash flow and slowed clinical trials.

  • DroppedRisks Related to Our Business

    As an intermediate step to commercial viability, we need to demonstrate that our IL-6 samples do not degrade over time, and our premise would be undermined if we fail to do so

  • DroppedRisks Related to Our Business

    We are currently only pursuing one aspect of analytical validation and we cannot be certain how long the remaining tests will take us

  • DroppedRisks Related to Our Business

    If we can not find a suitable CMO for the manufacturing of our Symphony cartridges, requiring additional costs and delaying FDA approval

    Placement agent fee dispute from prior 2023 and 2024 offerings.

  • DroppedRisks Related to Our Business

    We do not currently have sufficient supply to or know-how from Toray to reproduce the capture antibody in the Symphony IL-6 cartridges

  • DroppedRisks Related to Our Business

    We might not be able to discover the underlying cause of a Symphony performance reproducibility issue, and if the issues are inherent in the design of the platform we might have to redesign our approach

  • DroppedRisks Related to Product Development and Regulatory Approval

    After our Symphony IL-6 cartridges are redeveloped, transferred to a CMO, and pass analytical validation, our goal is to use the Symphony IL-6 test to complete the testing in the SYMON-II clinical trial

    Need to demonstrate IL-6 sample stability for commercial viability.

  • DroppedRisks Related to Product Development and Regulatory Approval

    We plan to redevelop the Symphony cartridge to achieve performance requirements. Delays in the redevelopment or transfer will negatively affect our timeline for the FDA submission of Symphony

  • DroppedRisks Related to Ownership of Our Common Stock

    The price of our common stock could decline if there are substantial sales of our common stock, particularly sales by our significant stockholders, or when there is a large number of shares of our common stock available for sale

  • DroppedRisks Related to Ownership of Our Common Stock

    We recently identified a material weakness in our internal control over financial reporting, and our business and stock price may be adversely affected if our internal control over financial reporting is not effective

    Scope of analytical validation studies including precision and linearity.

Reworded

  • 91% rewrittenRisks Related to Our Business

    If there is a shift in customer demand for the type of near-patient diagnostic test that we are working to develop, we would be left without a commercially marketable product in the pipeline

    Minor punctuation and wording cleanup regarding near-patient diagnostic test market demand.

  • 72% rewrittenRisks Related to Product Development and Regulatory Clearance

    The FDA may not clear or approve our product submissions or applications on a timely basis or at all. Such delays or refusals could have a material adverse effect on our business, financial condition, and results of operations

    Updated references from international regulatory approval processes to clearance processes.

  • 67% rewrittenRisks Related to Product Development and Regulatory Clearance

    We adapted our clinical trial design in 2023 to obtain more patient data to reflect recent FDA feedback, and our regulatory pathway remains subject to further FDA review and feedback and the results of ongoing and future clinical studies

    Updated clinical study status to reflect the completed SYMON-I pilot study and NCT06181604 clinical trial number.

  • 64% rewrittenRisks Related to Our Financial Condition and Capital Requirements

    We may be obligated to current and/or prior financial advisors under engagement letters that we enter into from time to time, and we are currently subject to such an obligation

    Removed the specific mention of Aegis Capital Corp. from financial advisor engagement letter disclosures.

  • 56% rewrittenRisks Related to Our Business

    We do not have a meaningful amount of authorized shares remaining under our equity compensation plans and therefore cannot incentivize our directors and employees with non-cash compensation, and our cash compensation obligations for directors and officers are substantial relative to our market capitalization

    Updated the cumulative reverse stock split ratio from 1-for-8,000 to 1-for-32,000.

    Was: We do not have a meaningful amount of authorized shares remaining under our equity compensation plans and therefore cannot incentivize our directors and employees with non-cash compensation

  • 52% rewrittenRisks Related to Our Business

    Specific raw materials used in the production of Symphony IL-6 cartridges are being limited in supply and the process of finding a suitable substitute could be expensive, use important resources, reduce the efficacy of the platform, or lead to other delays and setbacks

    Softened phrasing regarding raw material substitution from will need to validate to might need to validate.

    Was: Specific raw materials used in the production of Symphony IL-6 cartridges are being discontinued or are otherwise limited in supply and the process of finding a suitable substitute could be expensive, use important resources, reduce the efficacy of the platform, or lead to other delays and setbacks

  • 49% rewrittenRisks Related to Ownership of Our Common Stock

    We will continue incurring increased costs as a result of operating as a public company, and our management is now required to devote substantial time to new compliance initiatives and corporate governance practices

    Retained standard public company and Sarbanes-Oxley compliance cost disclosures.

  • 37% rewrittenRisks Related to Our Business

    In the event that we do not successfully address these risks, our business, prospects, financial condition, and results of operations could be materially and adversely affected

    Removed SanyoSeiko from the description of Toray license and manufacturing supply agreements.

  • 36% rewrittenRisks Related to Our Financial Condition and Capital Requirements

    We have incurred significant losses since our inception, do not currently generate any operating income, and expect to continue incurring losses as we work to obtain product approval, and thus we may never achieve or maintain profitability

  • 36% rewrittenRisks Related to Our Business

    FDA requirements could change prior to submission and lead to delays and additional costs

  • 34% rewrittenRisks Related to Ownership of Our Common Stock

    Sales of substantial amounts of our securities in the public market could depress the market price of our common stock

  • 34% rewrittenRisks Related to Our Business

    If we are not able to attract and retain highly skilled managerial, scientific and technical personnel, we may not be able to implement our business model successfully, and our limited cash resources could require us to make further cost reductions

All 51 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Financial Condition and Capital Requirements

  1. 01We have incurred significant losses since our inception, do not currently generate any operating income, and expect to continue incurring losses as we work to obtain product approval, and thus we may never achieve or maintain profitability36% rewritten
  2. 02We expect to need to raise at least $20 million between the date of this filing and the end of the 2027 fiscal year, and failure to do so could require us to undertake a process of liquidation under U.S. bankruptcy laws, which could cause holders of our common stock to recoup little, if any, value for their sharesNew
  3. 03Given the amount and terms of these warrants, we may find it more difficult to raise additional equity capital on favorable terms or at all while these warrants are outstandingNew
  4. 04Our ability to raise additional capital via a registered public offering on Form S-3 will be limited in the near-term as a result of the SEC’s “baby shelf” rules
  5. 05We may be obligated to current and/or prior financial advisors under engagement letters that we enter into from time to time, and we are currently subject to such an obligation64% rewritten

Risks Related to Our Business

  1. 06To preserve cash resources, we downsized our organization in 2025, which may reduce business continuity, affect our ability to apply for certain patents, and affect our product development and timelinesNew
  2. 07We are subject to the risks associated with new businesses
  3. 08In the event that we do not successfully address these risks, our business, prospects, financial condition, and results of operations could be materially and adversely affected37% rewritten
  4. 09As an intermediate step to regulatory submission, we need to demonstrate that our collected clinical samples do not degrade over timeNew
  5. 10There is a risk that validation of the primary outcome measure of our SYMON-I study will not achieve statistical significance
  6. 11There is a risk of our cartridges not passing analytical validation, one of the key requirements of FDA clearance
  7. 12FDA requirements could change prior to submission and lead to delays and additional costs36% rewritten
  8. 13The FDA could request additional data or testing after our application submission, requiring additional costs and delaying approval
  9. 14We depend on, and are liable for, Sanyoseiko as our Symphony analyzer and cartridge contract manufacturing organization (CMO), so its inability or failure to perform appropriately in that capacity may threaten our viability or have a material adverse effect on us and our business, assets and its prospects
  10. 15We have not yet launched any products and the ability to do so will depend on the acceptance of our Symphony platform in the healthcare market
  11. 16We cannot accurately predict the volume or timing of any sales, making the timing of any revenues difficult to predict
  12. 17If third-party payors do not provide coverage and reimbursement for the use of our platform, our business and prospects may be negatively impacted
  13. 18Our Symphony platform, including its software and systems, may contain undetected errors, which could limit our ability to provide our products and diminish the attractiveness of our offerings
  14. 19If we are not able to attract and retain highly skilled managerial, scientific and technical personnel, we may not be able to implement our business model successfully, and our limited cash resources could require us to make further cost reductions34% rewritten
  15. 20We do not have a meaningful amount of authorized shares remaining under our equity compensation plans and therefore cannot incentivize our directors and employees with non-cash compensation, and our cash compensation obligations for directors and officers are substantial relative to our market capitalization56% rewritten
  16. 21If we or our manufacturers fail to comply with the regulatory quality system regulations or any applicable equivalent regulations, our proposed operations could be interrupted, and our operating results would suffer
  17. 22Product liability suits, whether or not meritorious, could be brought against us due to an alleged defective product or for the misuse of our Symphony platform or test cartridges. These suits could result in expensive and time-consuming litigation, payment of substantial damages, and an increase in our insurance rates
  18. 23If we are found to have violated laws protecting the confidentiality of patient health information, we could be subject to civil or criminal penalties, which could increase our liabilities and harm our reputation or our business
  19. 24Significant raw material shortages, supplier capacity constraints, supplier disruptions, and sourcing issues may adversely impact or limit our products sales and or impact our product margins
  20. 25Specific raw materials used in the production of Symphony IL-6 cartridges are being limited in supply and the process of finding a suitable substitute could be expensive, use important resources, reduce the efficacy of the platform, or lead to other delays and setbacks52% rewritten
  21. 26We might not be able to resolve certain causes of a Symphony performance reproducibility issue, and if the issues persist we might have to take a different approachNew
  22. 27If there is a shift in customer demand for the type of near-patient diagnostic test that we are working to develop, we would be left without a commercially marketable product in the pipeline91% rewritten
  23. 28Healthcare legislative reform measures could have a material adverse effect on our business, future revenue, if any, and results of operationsNew

Risks Related to Product Development and Regulatory Clearance

  1. 29We adapted our clinical trial design in 2023 to obtain more patient data to reflect recent FDA feedback, and our regulatory pathway remains subject to further FDA review and feedback and the results of ongoing and future clinical studies67% rewritten
  2. 30The regulatory clearance process which we may be required to navigate may be expensive, time-consuming, and uncertain and may prevent us from obtaining clearance for our planned products
  3. 31Product clearances and approvals can often be denied or significantly delayed
  4. 32The FDA may not clear or approve our product submissions or applications on a timely basis or at all. Such delays or refusals could have a material adverse effect on our business, financial condition, and results of operations72% rewritten
  5. 33Clinical data obtained in the future may not meet the required objectives, which could delay, limit or prevent any regulatory clearance
  6. 34We may be unable to complete required clinical evaluations, or we may experience significant delays in completing such clinical evaluations, which could prevent or significantly delay our targeted product launch timeframe and impair our viability and business plan
  7. 35We and our suppliers may not meet regulatory quality standards applicable to our manufacturing processes, which could have an adverse effect on our business, financial condition, and results of operations
  8. 36We may be liable if the FDA or another regulatory agency concludes that we have engaged in the off-label promotion of our products
  9. 37Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of any future products and to manufacture, market and distribute our products after clearance or approval is obtained

Risks Related to Our Intellectual Property

  1. 38We depend on intellectual property licensed from Toray, and any dispute over the license would significantly harm our business
  2. 39We will depend primarily on Toray to file, prosecute, maintain, defend and enforce intellectual property that we license from it and that is material to our business
  3. 40We and Toray may be unable to protect or enforce the intellectual property rights licensed to us, which could impair our competitive position
  4. 41We and/or Toray may be subject to claims alleging the violation of the intellectual property rights of others
  5. 42We and Toray may be subject to claims challenging the invention of the intellectual property that we license from Toray

Risks Related to Our Industry

  1. 43We face intense competition in the diagnostic testing market, particularly in the IL-6 space, and as a result we may be unable to effectively compete in our industry
  2. 44If we or Toray fail to respond quickly to technological developments, our products may become uncompetitive and obsolete

Risks Related to Ownership of Our Common Stock

  1. 45Sales of substantial amounts of our securities in the public market could depress the market price of our common stock34% rewritten
  2. 46We could issue “blank check” preferred stock without stockholder approval with the effect of diluting interests of then-current stockholders and impairing their voting rights, and provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable
  3. 47We do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock
  4. 48If securities industry analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume of our common stock could be negatively affected
  5. 49Because we have elected to use the extended transition period for complying with new or revised accounting standards for an “emerging growth company” our financial statements may not be comparable to companies that comply with public company effective dates
  6. 50Anti-takeover provisions in our charter documents and Delaware law could discourage, delay or prevent a change in control of our Company and may affect the trading price of our common stock
  7. 51We will continue incurring increased costs as a result of operating as a public company, and our management is now required to devote substantial time to new compliance initiatives and corporate governance practices49% rewritten

Other Bluejay Diagnostics 10-Ks

  • FY2024 10-K risk factors
    56 risks

    Clinical trials and FDA submission for the Symphony platform are significantly delayed due to cash constraints and cartridge reproducibility issues. We rely heavily on single-source suppliers like Toray and contract manufacturers like SanyoSeiko without full technical know-how. We have incurred continuous net losses, including $10.0 million recently, and face going concern warnings.

    Filed Mar 31, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.